BridgeBio reports positive Phase 2 Cohort 5 data for infigratinib in achondroplasia; mean AHV increase +3.03 cm/yr

BridgeBio Pharma, Inc.

Mean change from baseline in annualized height velocity (AHV) at six months: +3.03 cm/yr (p=0.0022) in Cohort 5 (0.25 mg/kg daily).
80% of 10 children with six-month visits were responders (≥25% increase in AHV); mean change among responders +3.81 cm/yr.
No treatment-related adverse events in Cohort 5; no SAEs or discontinuations in any cohort.
BridgeBio has started enrolling children in a Phase 3 trial and plans to initiate development for hypochondroplasia.
Median absolute AHV reached 7.6 cm/yr, beyond the 99th percentile for achondroplasia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.